List of Excipients in Branded Drug ZONTIVITY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
WraSer Pharmaceuticals LLC	ZONTIVITY	vorapaxar	66992-208	CELLULOSE, MICROCRYSTALLINE	2027-12-23
WraSer Pharmaceuticals LLC	ZONTIVITY	vorapaxar	66992-208	CROSCARMELLOSE SODIUM	2027-12-23
WraSer Pharmaceuticals LLC	ZONTIVITY	vorapaxar	66992-208	FERRIC OXIDE YELLOW	2027-12-23

Zontivity Excipient Strategy and Commercial Opportunities for Vorapaxar

Last updated: August 29, 2026

Zontivity is an immediate-release oral tablet containing vorapaxar sulfate, a long-acting protease-activated receptor-1 antagonist. Its marketed formulation uses a conventional, low-cost excipient system: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and a hypromellose-based film coating. The largest commercial opportunities are unlikely to come from routine generic substitution alone. They are more likely to involve differentiated formulations, lactose-free products, adherence-oriented packaging, regional licensing, and lifecycle products that address the drug’s bleeding risk and prolonged pharmacology.

What is Zontivity and how is it used?

Zontivity contains 2.08 mg of vorapaxar sulfate, equivalent to 2 mg of vorapaxar. The FDA-approved dose is one tablet orally once daily, with or without food.

The drug is indicated for reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease. It is used with other antiplatelet or antithrombotic therapy when clinically appropriate.[1]

Attribute	Zontivity profile
Active ingredient	Vorapaxar sulfate
Active moiety	Vorapaxar
Dosage form	Immediate-release film-coated tablet
Strength	2.08 mg vorapaxar sulfate
Dose	Once daily
Therapeutic class	PAR-1 antagonist; antiplatelet agent
Sponsor	Merck & Co.
FDA approval	May 8, 2014
Key safety restriction	Contraindicated in patients with prior stroke, transient ischemic attack, intracranial hemorrhage, or active pathological bleeding
Pharmacologic issue	Long terminal elimination half-life, approximately eight days
Primary commercial market	Secondary prevention after myocardial infarction and peripheral arterial disease

The boxed warning concerns serious and potentially fatal bleeding. This safety profile has a direct effect on formulation strategy, target populations, market access, and commercial risk.

What excipients are used in the Zontivity tablet?

The commercial tablet uses a standard immediate-release excipient platform.

Core tablet excipients

The FDA prescribing information identifies the following inactive ingredients:

• Lactose monohydrate
• Microcrystalline cellulose
• Croscarmellose sodium
• Magnesium stearate

The film coating contains hypromellose, titanium dioxide, triacetin, and an iron oxide colorant.[1]

Excipient	Functional role	Commercial assessment
Lactose monohydrate	Diluent and bulking agent	Low cost, widely available; excludes patients with certain lactose sensitivities and may limit “lactose-free” positioning
Microcrystalline cellulose	Diluent, dry binder, compression aid	Supports tablet hardness and direct-compression manufacturing
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup and immediate release
Magnesium stearate	Lubricant	Controls ejection force but requires careful blending to avoid dissolution impact
Hypromellose	Film-forming polymer	Standard coating material for protection, appearance, and swallowability
Titanium dioxide	Opacifier and pigment	Conventional coating component, subject to regional regulatory and customer preferences
Triacetin	Plasticizer	Improves flexibility of the film coating
Iron oxide	Colorant	Supports product identification and brand differentiation

The formulation is commercially efficient because it does not depend on a specialized lipid system, amorphous solid dispersion, modified-release polymer, or device component. That simplicity reduces manufacturing barriers for a conventional immediate-release generic.

What formulation patents protect Zontivity?

The core intellectual-property position for vorapaxar has historically centered on the active compound, pharmaceutically acceptable salts, pharmaceutical compositions, and therapeutic use. The marketed dosage form itself appears to rely on conventional excipients rather than a visibly differentiated delivery technology.

The relevant patent categories are:

1. Compound patents covering vorapaxar or related tricyclic PAR-1 antagonists.
2. Salt and crystalline-form patents covering vorapaxar sulfate or solid-state forms.
3. Pharmaceutical-composition patents covering formulations containing vorapaxar.
4. Method-of-use patents covering thrombotic cardiovascular indications.
5. Manufacturing patents covering synthesis, purification, or crystallization.

The FDA Orange Book is the controlling public source for patents listed against the approved NDA. Orange Book listings can include patents with different claim scopes and expiration dates, and listed patents do not establish that every claim will survive validity or infringement challenges.[2]

Patent-strength assessment

Patent category	Potential relevance to generic entry	Strength assessment
Core compound claims	High if unexpired and valid	Usually the strongest barrier
Vorapaxar sulfate or crystal-form claims	High if the generic must use the same solid form	Depends on claim breadth and available alternative forms
Composition claims	Moderate	Weaker where the listed excipients are conventional or easily avoided
Method-of-use claims	Moderate to high	Depends on labeling, induced-infringement theories, and carve-out options
Manufacturing claims	Variable	Can be important if the process is difficult to design around
Film-coating claims	Low to moderate	Usually avoidable through alternative coating systems

A commercial diligence review should separate the marketed formulation from the broader vorapaxar patent estate. A generic may avoid a narrow excipient or coating claim while still confronting a compound, salt, crystal-form, or method-of-use patent.

When does Zontivity lose exclusivity?

Zontivity’s regulatory exclusivity and patent exclusivity are separate issues.

The five-year new chemical entity exclusivity period associated with the 2014 approval would have ended in 2019, subject to the applicable FDA reference-product rules. FDA approval exclusivity therefore does not represent the principal remaining barrier to entry.

The relevant patent term depends on the specific Orange Book-listed patent, patent-term adjustment, patent-term extension, terminal disclaimer, and any court or settlement outcome. The FDA Orange Book should be used to confirm the current listings and expiration dates before an ANDA, Paragraph IV certification, acquisition, or licensing decision.[2]

Exclusivity type	Relevance to Zontivity
New chemical entity exclusivity	Five years from FDA approval, subject to statutory rules
Three-year clinical investigation exclusivity	Not the primary historical barrier for the original NDA
Orphan-drug exclusivity	Not the principal basis for Zontivity’s approval
Patent exclusivity	Depends on active compound, formulation, use, and process patents
Pediatric exclusivity	Requires confirmation from current FDA records
Regulatory exclusivity after 2019	Limited compared with the patent position

Are there Paragraph IV challenges to Zontivity?

A Paragraph IV challenge would require an ANDA applicant to certify that a listed patent is invalid, unenforceable, or not infringed. The commercial effect would depend on whether the challenged patent covers the active ingredient, the salt or solid form, the formulation, or only a method of use.

Potential ANDA strategies include:

• Paragraph IV certification against compound or composition patents.
• Section viii carve-outs for patented indications that can be omitted from the generic label.
• Formulation design-around using alternative diluents, disintegrants, lubricants, or coating materials.
• Use of a different salt or solid form, where technically and legally feasible.
• Non-infringing manufacturing routes.
• Launch after patent expiration without a Paragraph IV challenge.

The risk profile is asymmetric. A product that avoids a formulation patent may still infringe a broader active-ingredient or solid-form claim. Conversely, a narrow method-of-use patent may have limited practical value if the generic label can omit the protected indication and physicians prescribe the product through permissible off-label use.

Publicly available FDA and court records should be reviewed for any current ANDA litigation, consent judgment, or settlement involving Zontivity. The presence or absence of a listed patent alone does not establish whether a generic launch is imminent.

What excipient strategies could support a Zontivity generic?

1. Conventional low-cost immediate-release formulation

The simplest strategy is to retain the same functional architecture while changing supplier grades or minor excipient proportions. Microcrystalline cellulose can provide compactibility, croscarmellose sodium can provide rapid disintegration, and magnesium stearate can support high-throughput tableting.

This approach offers:

• Low development cost.
• Established supply chains.
• Straightforward scale-up.
• Familiar dissolution testing.
• Lower regulatory complexity than a modified-release product.

The main technical risks are low-dose content uniformity, lubricant overmixing, tablet friability, and dissolution sensitivity.

2. Lactose-free formulation

Replacing lactose monohydrate with mannitol, anhydrous dibasic calcium phosphate, partially pregelatinized starch, or additional microcrystalline cellulose could support a lactose-free label.

Potential benefits include:

• Broader patient acceptability.
• Fewer excipient-related objections in institutional formularies.
• Differentiation in markets where lactose-free products are preferred.
• Simplified positioning for patients who report lactose intolerance.

The trade-off is that alternative diluents can change powder flow, tablet density, hardness, mouthfeel, and dissolution. A lactose-free formulation may require a new composition patent only if the formulation produces a meaningful technical effect, such as improved stability, content uniformity, or dissolution.

3. Improved content-uniformity platform

Vorapaxar is administered at a low dose relative to total tablet mass. A generic developer could use geometric dilution, ordered mixing, granulation, or carrier-based premixing to improve distribution of the active ingredient.

Commercially relevant claims could target:

• Narrow content-uniformity variability.
• Reduced segregation during high-speed compression.
• Improved blend stability.
• Lower tablet weight variation.
• Robustness across commercial batch sizes.

These improvements would not necessarily block competitors, but they could lower manufacturing failure rates and reduce cost of goods.

4. Taste and swallowability optimization

The marketed product is a swallowed film-coated tablet, so taste masking is not a central requirement. A smaller tablet, smoother film coat, or lower-friction surface could still improve adherence in older cardiovascular patients.

Opportunities include:

• Reduced tablet size through higher-density excipients.
• Alternative coating polymers.
• Improved coating uniformity.
• Unit-dose blister packaging paired with calendar labeling.

These changes are more likely to create commercial differentiation than strong patent exclusivity.

5. Modified-release or depot formulations

Vorapaxar already has prolonged pharmacologic activity. A controlled-release formulation would therefore face a difficult commercial justification. Slowing absorption may not provide a clear clinical benefit and could complicate management of bleeding events.

A modified-release product could be relevant only if it demonstrated:

• Lower peak exposure.
• Reduced bleeding risk.
• More consistent pharmacodynamic activity.
• Better tolerability.
• A clinically useful response to treatment interruption.

Without evidence of a safety or adherence advantage, the additional manufacturing cost and regulatory burden would likely outweigh the value of a modified-release product.

What commercial opportunities exist for Zontivity excipients?

Generic or authorized-generic supply

The most direct opportunity is supplying excipients for an immediate-release generic. The formulation uses commodity materials, so competition would be based on:

• Regulatory documentation.
• Consistent particle-size distribution.
• Low bioburden and elemental-impurity control.
• Reliable global supply.
• Technical support for direct compression.
• Ability to provide multiple compendial grades.

No single excipient appears indispensable. Supplier leverage would therefore come from quality performance, validation history, and manufacturing reliability rather than exclusivity.

Regional licensing

Vorapaxar has potential licensing value in regions where:

• Cardiovascular secondary prevention markets are expanding.
• Generic competition is limited.
• Local production is encouraged.
• Antiplatelet treatment guidelines support use in selected high-risk patients.

A regional partner would need to assess whether the bleeding warning, competing antiplatelet agents, and local reimbursement rules support a viable market.

Fixed-dose combinations

A fixed-dose combination with aspirin or another cardiovascular agent could improve pill burden, but it would raise important safety and regulatory issues. Vorapaxar is often used alongside antiplatelet therapy, yet combining agents in one tablet can reduce prescriber flexibility and complicate treatment interruption.

A combination product would require evidence that:

• The target population is sufficiently defined.
• Dose flexibility is not clinically important.
• Adherence gains offset the loss of titration flexibility.
• The combination does not create unacceptable bleeding exposure.

Adherence packaging

Calendarized blister packs, institutional unit-dose packaging, and medication-management kits are commercially more realistic than a new delivery system. They may be particularly relevant because vorapaxar’s long half-life makes missed doses and treatment discontinuation clinically consequential.

Packaging claims are generally easier to design around than active-ingredient claims and can create a service-based commercial proposition for specialty pharmacies, hospitals, and cardiovascular clinics.

How does Zontivity compare with competing antiplatelet drugs?

Zontivity competes with established antiplatelet therapies, including aspirin, clopidogrel, prasugrel, ticagrelor, and dual-antiplatelet regimens. These alternatives have broader prescribing familiarity and, in many cases, lower cost or shorter pharmacologic persistence.

Product	Mechanism	Differentiating characteristic	Commercial constraint
Zontivity	PAR-1 antagonist	Long-lasting platelet inhibition; distinct mechanism	Serious bleeding risk and long half-life
Aspirin	COX-1 inhibition	Low cost and broad familiarity	Gastrointestinal and bleeding risk
Clopidogrel	P2Y12 inhibition	Established generic option	Variable response and drug-interaction considerations
Prasugrel	P2Y12 inhibition	Potent platelet inhibition	Bleeding restrictions and population limitations
Ticagrelor	Reversible P2Y12 inhibition	Potent, reversible activity	Cost, dosing frequency, dyspnea, bleeding
Dual-antiplatelet therapy	Combined mechanisms	Stronger platelet inhibition	Higher bleeding risk and limited-duration use in many settings

Zontivity’s mechanism can support combination-therapy positioning, but that same positioning increases the importance of bleeding management. A formulation change that does not improve safety or adherence is unlikely to overcome the competitive disadvantage of a mature cardiovascular market.

What FDA regulatory issues affect a Zontivity reformulation?

A conventional ANDA formulation should generally demonstrate pharmaceutical equivalence and bioequivalence to the reference product. Changes in excipient type or level can affect dissolution, tablet disintegration, stability, and bioequivalence.

Key regulatory considerations include:

• Same active ingredient and strength.
• Same dosage form and route.
• Comparable release characteristics.
• Acceptable impurity and degradation profiles.
• Excipients permitted for the intended route and population.
• Demonstrated stability under proposed storage conditions.
• Appropriate labeling and contraindication language.
• Evaluation of inactive-ingredient differences under FDA requirements.

A new salt, new solid form, modified-release formulation, or fixed-dose combination would likely require a different regulatory pathway and could move beyond a standard ANDA strategy.

What manufacturing and IP barriers exist?

The principal manufacturing barriers are manageable but not trivial:

• Uniform distribution of a low-dose active ingredient.
• Control of blend segregation.
• Reproducible tablet hardness and disintegration.
• Avoidance of magnesium-stearate over-lubrication.
• Film-coat consistency.
• Control of vorapaxar-related impurities.
• Stable sourcing of pharmaceutical-grade excipients.

The principal IP barriers are more likely to arise from the active compound, sulfate salt, solid form, and method-of-use claims than from the marketed excipient system. A developer should conduct separate freedom-to-operate analyses for composition, process, labeling, and commercial packaging.

Key Takeaways

• Zontivity is a 2.08 mg vorapaxar sulfate immediate-release film-coated tablet.
• Its excipient system is conventional and includes lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, triacetin, and iron oxide.
• The most practical generic strategy is a conventional immediate-release tablet with an alternative excipient ratio or lactose-free formulation.
• Formulation patents are likely less significant than active-ingredient, salt, solid-form, method-of-use, and manufacturing patents.
• The principal commercial constraint is vorapaxar’s serious bleeding risk and prolonged half-life.
• Modified-release and fixed-dose combination products require a clear clinical benefit to justify development.
• Excipient suppliers can compete through quality, supply security, grade consistency, and technical support rather than exclusivity.
• The FDA Orange Book and current court records should control any assessment of patent expiration, Paragraph IV exposure, or generic launch timing.

FAQs About Zontivity Formulation and Commercialization

Can Zontivity be formulated without lactose?

Yes. Lactose monohydrate can potentially be replaced with mannitol, microcrystalline cellulose, starch-based excipients, or dibasic calcium phosphate, subject to compatibility, dissolution, stability, and bioequivalence requirements.

Is Zontivity a biologic requiring biosimilar approval?

No. Zontivity contains the small-molecule drug vorapaxar sulfate. A follow-on product would generally be evaluated through the generic-drug pathway rather than the biosimilar pathway.

Does Zontivity require a special controlled-release excipient?

No. The approved product is an immediate-release tablet. Its long pharmacologic effect comes from vorapaxar’s disposition and receptor activity rather than a marketed controlled-release matrix.

Could a new Zontivity formulation receive separate patent protection?

Potentially. A patent could cover a novel composition, solid form, manufacturing process, packaging system, or clinically meaningful release profile if the statutory patentability requirements are met.

What is the largest commercial risk for a Zontivity generic?

The largest risk is market size rather than basic tablet manufacturability. A generic developer must account for competing antiplatelet drugs, bleeding-related prescribing restrictions, treatment-selection guidelines, reimbursement, and the commercial status of the reference product.

References

1. U.S. Food and Drug Administration. (2014). Zontivity (vorapaxar sulfate) prescribing information. Merck Sharp & Dohme LLC. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. DailyMed. (n.d.). Zontivity: Vorapaxar sulfate tablet, film coated. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
4. Morrow, D. A., Braunwald, E., Bonaca, M. P., Ameriso, S. F., Dalby, A. J., Fish, M. P., Creager, M. A., Verheugt, F. W. A., O’Donoghue, M. L., Murphy, S. A., Figtree, G. A., Medlin, J., Kiss, R. G., and Scirica, B. M. (2012). Vorapaxar in the prevention of cardiovascular events. New England Journal of Medicine, 366(15), 1404-1413. https://doi.org/10.1056/NEJMoa1109719
5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/